Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion

Brian J Czerniecki, Gary K Koski, Ursula Koldovsky, Shuwen Xu, Peter A Cohen, Rosemarie Mick, Harvey Nisenbaum, Terry Pasha, Min Xu, Kevin R Fox, Susan Weinstein, Susan G Orel, Robert Vonderheide, George Coukos, Angela DeMichele, Louis Araujo, Francis R Spitz, Mark Rosen, Bruce L Levine, Carl June, Paul J Zhang
2007-02-15
Abstract:Overexpression of HER-2/neu (c-erbB2) is associated with increased risk of recurrent disease in ductal carcinoma in situ (DCIS) and a poorer prognosis in node-positive breast cancer. We therefore examined the early immunotherapeutic targeting of HER-2/neu in DCIS. Before surgical resection, HER-2/neupos DCIS patients (n = 13) received 4 weekly vaccinations of dendritic cells pulsed with HER-2/neu HLA class I and II peptides. The vaccine dendritic cells were activated in vitro with IFN-γ and bacterial lipopolysaccharide to become highly polarized DC1-type dendritic cells that secrete high levels of interleukin-12p70 (IL-12p70). Intranodal delivery of dendritic cells supplied both antigenic stimulation and a synchronized preconditioned burst of IL-12p70 production directly to the anatomic site of T-cell sensitization. Before vaccination, many subjects possessed HER-2/neu–HLA-A2 tetramer-staining CD8pos …
What problem does this paper attempt to address?